MSTN and Duchenne muscular dystrophy: Treatment of normal rodentsand dystrophin-deficient mdx mice with factors that block myostatin signaling,such as a soluble myostatin receptor, a propeptide, or follistatin, showedsignificant increases in muscle mass and improved muscle regeneration [139, 140].The myostatin antibody MYO 029 is currently in Phase II clinical trials fortreatment of Duchenne muscular dystrophy.